3 results
8-K
EX-99.1
RLAY
Relay Therapeutics Inc
8 Jan 24
Entry into a Material Definitive Agreement
7:05am
comparisons cannot be made, and no head-to-head clinical trials have been conducted. Most closely approximates ReDiscover demographics among these trials … + fulvestrant Capivasertib + fulvestrant Most closely approximates ReDiscover demographics among these trials* Doublet Combination Regimens HbA1C
8-K
EX-99.2
RLAY
Relay Therapeutics Inc
8 Aug 23
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
4:14pm
mono
RLY-2608 – ReDiscover Trial Breast Cancer Baseline Demographics and Genotype RLY-2608 + fulvestrant(N=39) RLY-2608 + fulvestrant 600 mg BID(N
8-K
EX-99.1
RLAY
Relay Therapeutics Inc
18 Apr 23
Regulation FD Disclosure
10:42am
Trial – Baseline Demographics and Tumor Genotype RLY-2608 (N=19) RLY-2608 + fulvestrant(N=23) Total (N=42) Age, median (range), years 63 (42-85) 57
- Prev
- 1
- Next